Comparison of estimated survival of patients with de novo AMKL (FAB subtype M7) without DS with that of patients with other subtypes of de novo AML (FAB M0-M6).

All patients were treated on 4 St Jude Children's Research Hospital frontline AML protocols (AML-83, AML-87, AML-91, AML-97) between January 1985 and December 1998. Estimated 5-year survival was 10% (95% CI = 0%-22%) for de novo AMKL and 42% (95% CI = 34%-50%) for non-M7 de novo AML (P < .001).